Melissa Epperly - Oct 4, 2023 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Stock symbol
ZNTL
Transactions as of
Oct 4, 2023
Transactions value $
-$106,926
Form type
4
Date filed
10/6/2023, 07:18 PM
Previous filing
Sep 14, 2023
Next filing
Oct 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$89.2K -4.59K -1.17% $19.43 389K Oct 4, 2023 Direct F1, F2, F3
transaction ZNTL Common Stock Sale -$17.7K -888 -0.23% $19.91 388K Oct 4, 2023 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.